- |||||||||| Opdivo (nivolumab) / BMS
Journal, Pleural effusion: Intrapleural nivolumab in cancer patients with pleural effusion. (Pubmed Central) - Jul 18, 2024 No adverse events were identified. We concluded that a single intrapleural instillation of the nivolumab at 40 mg was ineffective and well-tolerated in cancer patients with pleural effusion.
- |||||||||| oleclumab (MEDI9447) / AstraZeneca, monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
P3 data, Journal: PACIFIC-9: Phase III trial of durvalumab (Pubmed Central) - Jul 18, 2024 P3 Both agents demonstrated antitumor activity in early-phase trials. PACIFIC-9 (NCT05221840) is an international, double-blind, randomized, placebo-controlled, Phase III trial comparing durvalumab plus either oleclumab or monalizumab with durvalumab plus placebo in patients with unresectable, stage III NSCLC and no disease progression following cCRT.Clinical Trial Registration: NCT05221840 (ClinicalTrials.gov).
- |||||||||| Nplate (romiplostim) / Amgen, Kyowa Kirin
Clinical data, Retrospective data, Journal: Romiplostim for treatment of thrombocytopenia in dogs: A retrospective assessment and clinical outcomes. (Pubmed Central) - Jul 18, 2024 Romiplostim is a well-tolerated and promising treatment for primary ITP in dogs, suggesting its potential as a valuable therapeutic option for dogs with thrombocytopenia caused by various underlying conditions. These findings emphasize the need for further research to optimize romiplostim dosing and understand its role in treating secondary thrombocytopenia and pancytopenia of unknown etiology.
- |||||||||| GSK5733584 / GSK
Enrollment open, Metastases: HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors (clinicaltrials.gov) - Jul 18, 2024 P1, N=1048, Recruiting, The present report provides a new treatment strategy by incorporating CDK4/6 inhibitors in the therapeutic armamentarium of breast NECs. Not yet recruiting --> Recruiting
- |||||||||| Rituxan (rituximab) / Roche
Pain and MRI correlates in patients with stiff person syndrome (Exhibition Hall/Poster Area) - Jul 18, 2024 - Abstract #IASP2024IASP_1913; Chronic pain is reflected in the brain MRI by reduced prefrontal cortical thickness, and GAD autoantibody titers correlate negatively with GABA levels in the insular cortices. The causally oriented immunotherapies and symptomatic GABAergic treatment appear to have an analgesic action.
- |||||||||| Ocrevus (ocrelizumab) / Roche
Journal: Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation. (Pubmed Central) - Jul 18, 2024 Therapy with ocrelizumab, teriflunomide or dimethyl fumarate reduced EBV-specific, but not CMV-specific MHC-I-restricted TRB sequence matches. Together, this data suggests that the aberrant MHC-I-restricted T-cell response directed against EBV is specific to MS with regard to NMO, MOGAD and Susac's Syndrome and that it is specifically modified by MS treatments interfering with EBV host cells or activated lymphocytes.
- |||||||||| Promacta (eltrombopag) / Novartis
Journal: Safety and efficacy of immunosuppressive therapy for elderly patients with severe aplastic anaemia. (Pubmed Central) - Jul 18, 2024 Uncertainty remains regarding the safety and tolerability of immunosuppressive therapy (IST) with anti-thymocyte globulin (ATG) and cyclosporine (CSA) in older patients...Patients ?18?years of age who had received IST with ATG and CSA +/- eltrombopag (EPAG) were included...Disease-related factors and limited therapeutic options in refractory disease likely contribute to poorer outcomes in older patients, not complications of upfront IST. Therefore, IST should be considered first-line therapy for most older SAA patients.
- |||||||||| Avastin (bevacizumab) / Roche, adebrelimab (SHR-1316) / Jiangsu Hengrui Pharma
Enrollment open, Enrollment change, Trial completion date, Trial primary completion date: A Phase II Study of Triple-negative Breast Cancer Brain Metastases. (clinicaltrials.gov) - Jul 18, 2024 P2, N=35, Recruiting, The trial will yield important information to guide routine management of patients with local advanced rectal cancer. Unknown status --> Recruiting | N=59 --> 35 | Trial completion date: Jan 2022 --> May 2025 | Trial primary completion date: Dec 2021 --> Dec 2024
- |||||||||| Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date, IO biomarker: Nivolumab for Recurrent or Progressive IDH Mutant Gliomas (clinicaltrials.gov) - Jul 18, 2024 P2, N=20, Active, not recruiting, Unknown status --> Recruiting | N=59 --> 35 | Trial completion date: Jan 2022 --> May 2025 | Trial primary completion date: Dec 2021 --> Dec 2024 Trial completion date: Dec 2022 --> Dec 2026 | Trial primary completion date: Dec 2022 --> Jun 2025
- |||||||||| Opdivo (nivolumab) / BMS, Repatha (evolocumab) / Amgen, Astellas, Yervoy (ipilimumab) / BMS
Trial completion date, Trial primary completion date, Combination therapy, Metastases: TOP2101: A Randomized Pilot Study of Evolocumab Plus Nivolumab/Ipilimumab in Treatment-Na (clinicaltrials.gov) - Jul 17, 2024 P2, N=38, Recruiting, Active, not recruiting --> Recruiting Trial completion date: Dec 2025 --> Jun 2027 | Trial primary completion date: Dec 2023 --> Jun 2025
- |||||||||| datopotamab deruxtecan (DS-1062a) / Daiichi Sankyo, AstraZeneca, Imfinzi (durvalumab) / AstraZeneca
New P1/2 trial, Metastases: COMPASS-TNBC: A Study to Explore Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Novel Therapeutics in Patients With Early Relapsed Metastatic Triple-negative Breast Cancer (clinicaltrials.gov) - Jul 17, 2024 P1/2, N=50, Recruiting,
- |||||||||| COM701 / Compugen
Trial completion, Trial completion date, Combination therapy, Monotherapy, Metastases: COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - Jul 17, 2024 P1, N=121, Completed, Trial primary completion date: Jul 2024 --> Jun 2026 Active, not recruiting --> Completed | Trial completion date: May 2024 --> Jan 2024
- |||||||||| GEN1047 / Genmab
Trial completion date, Trial primary completion date: GCT1047-01: GEN1047 for Solid Tumors - First in Human (FIH) Trial (clinicaltrials.gov) - Jul 17, 2024 P1/2, N=400, Recruiting, Trial primary completion date: Jun 2024 --> Dec 2024 Trial completion date: Jun 2026 --> Mar 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
- |||||||||| bintrafusp alfa (M7824) / EMD Serono
Trial completion date, Trial primary completion date, Tumor mutational burden: M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers (clinicaltrials.gov) - Jul 17, 2024 P1/2, N=80, Recruiting, Serial CNS scans were studied from LIBRETTO-431, a randomized phase III trial of selpercatinib versus platinum/pemetrexed Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2027
- |||||||||| Bavencio (avelumab) / EMD Serono, Talzenna (talazoparib) / Pfizer
P2 data, Journal, Metastases: A Phase 2 Trial of Talazoparib and Avelumab in Genomically Defined Metastatic Kidney Cancer. (Pubmed Central) - Jul 17, 2024 Nevertheless, further investigations focusing on metastatic organotropism differential response with reliable oncological outcomes are needed to identify the optimal management strategy for these patients. The first clinical study of combination PARPi and ICB therapy in advanced kidney cancer did not show clinical benefit in multiple genomically defined metastatic RCC cohorts or RMC.
- |||||||||| Venclexta (venetoclax) / Roche, AbbVie, Rituxan (rituximab) / Roche
Trial primary completion date, Combination therapy: VIWA-1: Efficacy of Venetoclax in Combination With Rituximab in Waldenstr (clinicaltrials.gov) - Jul 17, 2024 P2, N=80, Not yet recruiting, These results warrant an evaluation of the prognostic value of adrenal metastases in patients treated with immunotherapy combinations with ipilimumab or tyrosine kinase inhibitors. Trial primary completion date: Oct 2027 --> Jan 2028
- |||||||||| Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: Surgical Nivolumab And Ipilimumab For Recurrent GBM (clinicaltrials.gov) - Jul 17, 2024 P1, N=63, Active, not recruiting, Trial primary completion date: Oct 2027 --> Jan 2028 Trial primary completion date: Jun 2024 --> Dec 2024
|